The invention provides a method of efficiently and stably producing ?-form crystal of reduced glutathione, and a preservation method thereof. According to the invention, development of ?-form crystal and/or transition to ?-form crystal of reduced glutathione are suppressed by the coexistence of at least one kind of compound selected from the group of aliphatic amino acid, sulfur-containing amino acid, aromatic amino acid, an analogous compound and dipeptide, as a habit modifier, during production and preservation of an aqueous solution or ?-form crystal of reduced glutathione.

The present disclosure provides methods and reagents useful for analyzing protein-protein interfaces such as interfaces between a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein. In some embodiments, the target and/or presenter proteins are intracellular proteins. In some embodiments, the target and/or presenter proteins are mammalian proteins.

The present invention relates to a compound simultaneously having triple activities of thrombolysis, antithrombosis and free radical scavenging, as well as the preparation method, composition, and applications thereof. The compound is represented by the formula I shown below:

##STR00001##

wherein the definitions of T, Q, R.sub.1 and R.sub.2 are described herein. The compound of the present invention simultaneously has triple functions of thrombolysis, free radical scavenging and thrombus-targeting/antithrombosis. The present invention also relates to a pharmaceutical composition comprising the compound, and a preparation method and a nanostructure of the compound.

Methods and pharmaceutical compositions for inhibiting or decreasing transport of a drug by a transporter of multidrug resistance-associated protein are provided.

Compounds for targeting and agents for imaging, prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.

A peptide-urea derivative, a pharmaceutical composition containing same and an application thereof are provided, the derivative being as shown in formula I. The derivative can be used for preoperative imaging diagnosis and grading of PSMA-positive prostate cancer, and can also be used for the treatment of various types and stages of prostate cancer, achieving the integration of diagnosis and treatment, and having broad application prospects.

##STR00001##

The present invention provides a crystal of reduced glutathione that is stable, and is easy to process, and a method for producing the crystal. According to the present invention, a crystal of a metal salt of reduced glutathione is produced by suspending an amorphous solid of a metal salt of reduced glutathione in a hydrophobic organic solvent, and adding water to the resulting suspension to precipitate a crystal of a metal salt of reduced glutathione.

Compounds are described herein where CCK2R targeting ligands are attached to an imaging agent through a linker. The compounds can be used in the detection, diagnosis, imaging and treatment of cancer.

The present invention relates to a compound simultaneously having triple activities of thrombolysis, antithrombosis and free radical scavenging, as well as the preparation method, composition, and applications thereof. The compound is represented by the formula I shown below: ##STR00001##
wherein the definitions of T, Q, R.sub.1 and R.sub.2 are described herein. The compound of the present invention simultaneously has triple functions of thrombolysis, free radical scavenging and thrombus-targeting/antithrombosis. The present invention also relates to a pharmaceutical composition comprising the compound, and a preparation method and a nanostructure of the compound.

The present invention provides a compound having the structure: ##STR00001## wherein X is a therapeutic agent containing at least one amine nitrogen and the amine nitrogen on the therapeutic agent covalently bonds directly to carbon ; Z is CH.sub.3 or CF.sub.3; R.sub.1 is H, NR.sub.2R.sub.3, NHC(O)R.sub.4, NHC(O)OR.sub.4, CH.sub.2C(O)NR.sub.5R.sub.6, OR.sub.7, CO.sub.2R.sub.7, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, aryl, or heteroaryl, wherein R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6 and R.sub.7 are each, independently, H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, an amino acid or an oligopeptide; wherein an amine of the amino acid or oligopeptide is substituted or unsubstituted; and n is an integer from 0 to 6;
or a diastereomer, enantiomer or pharmaceutically acceptable salt of the compound.